Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603809 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,659
- Enrollment target
NCT02603809 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 1,659 participants.
The verdict
NCT02603809, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,659 participants
- Enrollment target
Study Summary
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.
Interventions
- DRUG Aprocitentan 5 mg
- DRUG Aprocitentan 10 mg
- DRUG Aprocitentan 25 mg
- DRUG Aprocitentan 50 mg
- DRUG Lisinopril 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,659 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2017-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603809
The ClinicalTrials.gov registry entry for NCT02603809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,659 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aprocitentan 5 mg is the first listed.
NCT02603809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603809 about?
NCT02603809 is a clinical study titled "Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension". The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and r...
What is the current status of trial NCT02603809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,659 participants. The study started on 2015-12-14. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT02603809?
The interventions under investigation include: Aprocitentan 5 mg (DRUG), Aprocitentan 10 mg (DRUG), Aprocitentan 25 mg (DRUG), Aprocitentan 50 mg (DRUG), Lisinopril 20 mg (DRUG).
Who is sponsoring clinical trial NCT02603809?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.